New Lundbeck candidate to kick off R&D division
With the acquisition of the biotherapy candidate from South Korean Aprilbio, Lundbeck has obtained the first development program within a new strategic focus area, neuroimmunology. Lundbeck's EVP and research lead is keeping his cards close about potential drug indications.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
Since Lundbeck went through a larger shift in its research and development division, the company has been busy scouting for assets that could fit in its new focus area, neuroinflammation or neuroimmunology.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck silent on shutdown of Indian operations
For subscribers
Lundbeck CEO considers stepping up marketing of Vyepti
For subscribers
.jpg)
.jpg&w=384&q=75)
